We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.31%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.71B
AUM Growth
+$121M
Cap. Flow
+$218M
Cap. Flow %
5.87%
Top 10 Hldgs %
63.73%
Holding
72
New
5
Increased
8
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$120M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$47.8M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$38.2M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.6M
5
ROIV icon
Roivant Sciences
ROIV
+$31M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$67.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$10.1M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.73M
4
RLAY icon
Relay Therapeutics
RLAY
+$8.12M
5
ITOS
iTeos Therapeutics
ITOS
+$7.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.61B
$1.24B 33.43%
21,751,284
– –
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.76B
$182M 4.9%
4,004,613
+1,158,598
+41% +$47.8M
AXSM icon
3
Axsome Therapeutics
AXSM
$11.8B
$149M 4.02%
2,131,100
– –
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.49B
$143M 3.84%
5,283,489
-400,000
-7% -$10.1M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.73B
$138M 3.72%
+4,370,024
New +$120M
OLMA icon
6
Olema Pharmaceuticals
OLMA
$1.03B
$113M 3.04%
9,135,893
+1,524,390
+20% +$15.5M
RVMD icon
7
Revolution Medicines
RVMD
$40.4B
$110M 2.97%
3,981,212
-2,274,376
-36% -$67.5M
RPTX
8
DELISTED
Repare Therapeutics
RPTX
$100M 2.7%
8,291,988
– –
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.7B
$95.8M 2.58%
5,744,848
+1,968,948
+52% +$38.2M
GHRS icon
10
GH Research
GHRS
$1.96B
$93.2M 2.51%
9,275,158
– –
GPCR icon
11
Structure Therapeutics
GPCR
$3.46B
$88.2M 2.38%
1,750,000
– –
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$70.5M 1.9%
10,563,748
– –
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$66.2M 1.78%
1,915,109
-250,000
-12% -$9.73M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.72B
$65.9M 1.78%
4,739,004
– –
MRUS
15
DELISTED
Merus
MRUS
$64.9M 1.75%
2,752,420
+1,150,000
+72% +$27.9M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.12B
$62.4M 1.68%
1,827,958
– –
KURA icon
17
Kura Oncology
KURA
$830M
$61.4M 1.66%
6,730,983
– –
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$58.9M 1.59%
9,103,054
-320,161
-3% -$2.19M
XOMA
19
DELISTED
Xoma
XOMA
$51.2M 1.38%
3,633,743
– –
FDMT icon
20
4D Molecular Therapeutics
FDMT
$544M
$51M 1.38%
4,007,413
– –
ACRS icon
21
Aclaris Therapeutics
ACRS
$736M
$48.4M 1.31%
7,064,736
+3,703,795
+110% +$31.6M
JANX icon
22
Janux Therapeutics
JANX
$940M
$46.2M 1.24%
4,579,818
+472,873
+12% +$5.45M
TYRA icon
23
Tyra Biosciences
TYRA
$1.95B
$37.7M 1.02%
2,739,595
– –
ZYME icon
24
Zymeworks
ZYME
$1.66B
$37.2M 1%
5,870,000
– –
REPL icon
25
Replimune Group
REPL
$967M
$36.7M 0.99%
2,143,036
– –
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2023 Portfolio in Review

As of Q3 2023, BVF Inc held 72 positions worth $3.71B, up 3.4% from $3.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2023, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $67.5M trimmed.

  • BVF Inc's largest Q3 2023 buy was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2023, an estimated $47.8M increase.
  • BVF Inc's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $67.5M.
  • BVF Inc fully exited Aravive, Inc. Common Stock in Q3 2023, selling an estimated $6.03M.
  • BVF Inc's ten largest holdings make up 64% of its $3.71B portfolio in Q3 2023.
  • BVF Inc opened 5 new positions and closed 3 in Q3 2023.
  • BVF Inc's portfolio value rose 3.4% quarter-over-quarter to $3.71B.

Based on BVF Inc's 13F filing for Q3 2023, filed 14 Nov 2023.